PDIA6 Contributes to Aerobic Glycolysis and Cancer Progression in Oral Squamous Cell Carcinoma

Ling Mao
Guizhou Medical University

Xiaoweng Wu
Liaocheng People's Hospital

Zhengpeng Gong
The Affiliated Hospital of Guizhou Medical University

Ming Yu
The affiliated Baiyun Hospital of Guizhou Medical University

Zhi Huang (✉️ doctor@huangzhi.com)
Guizhou Medical University  https://orcid.org/0000-0001-9020-897X

Research

Keywords: PDIA6, proliferation, migration, aerobic glycolysis, tumorigenesis

DOI: https://doi.org/10.21203/rs.3.rs-96935/v1

License: ☒  This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background/Objective: Accumulated evidence has demonstrated that aerobic glycolysis serves as a regulator of tumor cell growth, invasion and angiogenesis. Herein, we explored the role of protein disulfide isomerase family 6 (PDIA6) in the aerobic glycolysis and the progression of oral squamous cell carcinoma (OSCC).

Methods: The expression pattern of PDIA6 in OSCC tissues was determined by qPCR and western blotting. Lentivirus and small interfering RNAs (siRNAs) were introduced into cells to upregulate and downregulate PDIA6 expression. CCK-8, flow cytometry, transwell and xenotransplantation models were applied to detect cell proliferation, apoptosis, migration, invasion and tumorigenesis, respectively.

Results: A high expression pattern of PDIA6 was observed in OSCC tissues, which was closely associated with lower overall survival and malignant clinical features in OSCC. Compared with the control group, overexpression of PDIA6 induced significant enhancements in cell growth, migration, invasiveness and tumorigenesis and decreased cell apoptosis, while knockdown of PDIA6 caused opposite results. In addition, overexpression of PDIA6 increased glucose consumption, lactate production and ATP level in OSCC cells.

Conclusion: This study demonstrated that PDIA6 expression was elevated in OSCC tissues, and overexpression of it promoted OSCC progression and aerobic glycolysis.

Introduction

Oral squamous cell carcinoma (OSCC), as a major type of head and neck cancer, ranks the sixth most common malignant tumor in the world, and ranks eighth in cancer-related mortalities (1). It is estimated that about 354, 800 new cases who are diagnosed with OSCC and 177, 400 deaths caused by OSCC annually (2). Despite big processes have been achieved in treatment and diagnosis, the five-year survival rate for OSCC is only about 50% (3, 4). The high invasiveness and metastasis are two main reasons for the worse outcome of OSCC, with the local and regional recurrence rate about 33%~40% (5). Thus, it is helpful to uncover the molecular mechanisms underlying OSCC.

Aerobic glycolysis, also known as the Warburg effect, is one of the main features of cancer cells (6, 7). Generally, glucose uptake and lactate production are increased in tumor cells via the aerobic glycolysis pathway to meet the requirement of elevated bioenergetic and biosynthetic demand for growth, metastasis and invasion, leading to lactate content increase and pH value decrease (8). Evidence has demonstrated that elevated lactate level is closely associated with tumor growth, invasion and angiogenesis (9, 10). For example, Cai et al (11) reported that lactate dehydrogenase A (LDHA) was highly expressed in OSCC tissues and cell lines, and knockdown of it repressed cell proliferation, migration and invasion and in vivo tumor formation through inhibiting glycolysis. Targeting aerobic glycolysis pathway is a promising method for cancer treatment (12).
Protein disulfide isomerase family 6 (PDIA6), also known as ERP5 or P5, belongs to the protein disulfide isomerase (PDI) family that assists protein folding and inhibits the polymerization of unfolded substrates and oxidoreductases to facilitate the formation of disulfide bonds (13, 14). Recently, researches have demonstrated that PDIA6 is overexpressed in several kinds of human cancers and serves as an oncogene, such as lung cancer (15), bladder cancer (16) and hepatocellular carcinoma (17). However, whether PDIA6 is involved in the aerobic glycolysis and the progression of OSCC still need to be elucidated.

In the present study, we aimed to explore the expression pattern of PDIA6 in OSCC tissues and to reveal its role in the aerobic glycolysis and the progression of OSCC.

**Materials And Method**

**Ethics statement**

The current study has got the approval of the ethics committee of Guizhou Medical University (No. 2001221).

**Clinical tissue samples**

Fifty-eight OSCC tissues and the adjacent noncancerous tissues were obtained from patients with primary OSCC undergoing surgical resection. No patients received chemotherapy or radiotherapy prior to surgery. All specimens were confirmed by two pathologists. The written informed consents were signed by every patient and the current study has got the approval of the ethics committee of Guizhou Medical University. All tissue samples were rapidly placed at −80°C for further study. The OSCC patients were divided into PDIA6 high expression and low expression groups based on the expression medium of PDIA6 at mRNA level.

**Cell lines and culture method**

Two human OSCC cell lines, SCC9 and Cal27 were all purchased from ATCC (Manassas, VA, USA). SCC9 cells were seeded in Eagle's medium and Ham's F12 medium, and Cal27 cells were placed in DMEM, with 10% fetal bovine serum (FBS) and 1% (v/v) penicillin/streptomycin. All cells were kept in a humidified atmosphere with 5% CO₂ with a stationary temperature of 37°C. Cell culture medium and FBS were purchased from Invitrogen (Carlsbad, CA, USA).

**Lentivirus and small interfering RNAs (siRNAs)**

The lentivirus vectors applied to overexpress PDIA6 (called OE-PDIA6), and the siRNA used to downregulate PDIA6 (called as si-PDIA6) and their negative controls (OE-NC, si-NC) were all purchased from Shanghai GenePharma Co., LTD (Shanghai, China). The lentivirus vectors were introduced into cells via cell infection by using polybrene, and si-PDIA6 and si-NC were introduced into cells via cell
transfection using Lipofectamine 2000 reagent (Invitrogen). The infected cells were incubated in G418 (100 μg/ml) for 14 days to establish the stable cell lines which were used in the *in vivo* assay.

**Real-time quantitative polymerase chain reaction (qPCR)**

Total RNA was extracted from tissues and cells by using TRizol reagent (Life Technologies, Waltham, MA, USA) referring to the manufacturer's manual. Then, the cDNA was produced using a PrimeScript™ 1st Strand cDNA Synthesis Kit (Takara, Dalian, China). After that, the cDNA was served as substrate for qPCR with SYBR Premix Ex Taq (Takara) on an ABI 7900 system (Applied Biosystems, Foster City, CA, USA). The $2^{-\Delta\Delta Ct}$ method was applied to analyze the relative levels of mRNAs after being normalized to that of the expression level of β-ACTIN. The sequences used in this experiment were listed in Table 1.

**Western blotting assay**

Total protein was obtained from cells using the RIPA lysis buffer (Beyotime, Jiangsu, China), supplemented with 1% (v/v) protease inhibitors (Beyotime). Then, 30 μg protein sample obtained from every group was separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by transformation into the polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The membranes were then successively incubated with 5% fat-free milk for 1 hour at room temperature and proved with the first antibodies, including PDIA6 (1:2,000 dilution; No. ab11432, Abcam, Cambridge, MA, USA), and β-actin (No. ab8226, Abcam, 1:5,000 dilution) overnight at 4°C. After that, the membranes were probed with secondary antibodies (Abcam) for 1 hour. Protein signals were detected using iBright CL750 (Thermo Fisher Scientific, MA, USA) after incubation with ECL (Thermo Fisher Scientific).

**CCK-8 assay**

The proliferation assay was performed with the Cell Counting Kit-8 (CCK-8) assay. First, the OSCC cells (2500 cells for each well) were seeded in 96-well plates, allowed to adhere, transfected and then cultured at 37 °C for 0, 24, 48 and 72 hours. Then, 10 μL CCK-8 solution (Abcam) was added to each well and allowed to incubate for further 4 hours at 37°C. The OD values at 450 nm were determined using a spectrophotometer (BioTek Instruments, Winooski, VT, USA).

**Transwell chamber assay**

Cell metastasis and invasiveness were assessed with Transwell chambers (8 μm, Corning, NY, USA) in 24 well plates using uncoated or Matrigel-(BD Biosciences, San Jose, USA) coated membranes. In briefly, OSCC cells in culture medium with 1% FBS were seeded in the upper well with $1 \times 10^5$ cells for each well, and 600 μL cell culture medium with 10% FBS was added in the lower chambers. After 24 hour or 48 hours of incubation, the cells did not penetrate the membrane on the upper chamber were removed with a cotton swab. Cells in the lower membrane were fixed with methanol and stained with 0.1% crystal violet solution. After washing with PBS for 4-5 times, the numbers of stained cells in 6 random fields were counted under an inverted microscope.
Detection of lactate production, glucose consumption and ATP levels

OSCC cells were inoculated in 6-well plates at a density of 2×10^5 cells and allowed to attach. Following 24 hours of incubation, the medium was collected to measure lactate production and glucose consumption with commercial kits from Nanjing Jiancheng Biotech (Jiangsu, China; A019) and Applygen Co., LTD (Beijing, China; No. E1010) in the light of the manufacturer's descriptions, respectively. ATP levels were tested using an ATP Colorimetric/Fluorometric Assay Kit (Sigma-Aldrich, MO, USA) in the light of manufacturer's instructions.

Tumor xenograft

Male NOD/SCID mice aged 5–6 weeks obtained from Wuhan Huaguenke Biotechnology Co. LTD (Hubei, China) were randomly divided into OE-NC and OE-PDIA6 groups (n=5 for each group). This animal assay has got the approval of the Experiment Ethics Committee of Guizhou Medical University. Approximately 5×10^6 SCC9 cells with OE-NC or OE-PDIA6 stable transfection were suspended in 200 μl of PBS and then subcutaneously injected into the armpit of mice. The tumors were measured to assess tumor formation every week. Tumor volume = length × width^2/2. The mice were euthanized 4 weeks after injection, and the tumor xenografts were harvested and weighed.

Statistical analysis

Data are expressed as mean ± standard deviation (SD) from 3 independent experiments. SPSS software (version 23.0, SPSS Inc., Chicago, IL, USA) was applied for statistical analyses. Correlations were determined by Pearson correlation analysis. Two-side t tests and one-way ANOVA with Bonferroni post-hoc tests were used to compare differences between two and ≥ 3 groups. The value of \( p < 0.05 \) was considered as statistically significant.

Results

PDIA6 was overexpressed in OSCC tissues

To explore the role of PDIA6 in the progression of OSCC, we first assessed its expression profile in OSCC tissues. Compared with the adjacent noncancerous tissues, the expression of PDIA6 was significantly elevated in cancer tissues at both mRNA and protein levels, as detected by qPCR (Figure 1A) and western blotting (Figure 1B). This result suggested that the high expression of PDIA6 might play a role in the progression of OSCC.

PDIA6 high expression predicted poor prognosis and malignant clinical clinicopathologic feature in OSCC

Then, we evaluated the clinical value of PDIA6 in OSCC. The overall survival for patients with PDIA6 high expression group was significantly lower than that of the PDIA6 low expression group (Figure 1C). In addition, high expression level of PDIA6 was closely associated with higher TNM stage \( (p=0.006) \), poorer tissue differentiation \( (p=0.036) \) and perineural invasion \( (p=0.034) \) in OSCC patients. This result
demonstrated that the high expression level of PDIA6 predicted poor prognosis and malignant clinical clinicopathologic feature in OSCC.

**PDIA6 promoted cell growth and inhibited cell apoptosis in OSCC**

Next, gain- and loss-of-function experiments were carried out to assess PDIA6 role in cell proliferation and apoptosis in OSCC cells. PDIA6 expression was significantly increased following cell infection with OE-PDIA6 in SCC9 and Cal27 cells, while PDIA6 level was decreased when cells were transfected with si-PDIA6 at mRNA and protein levels (Figure 2A-2B). Cell proliferation was significantly enhanced while apoptosis was inhibited when PDIA6 was overexpressed in SCC9 and Cal27 cells, while knockdown of PDIA6 induced an obvious repression in cell proliferation and a significant increase in cell apoptosis rate (Figure 2C-2F). These results demonstrated that PDIA6 promoted OSCC cell growth and inhibited cell apoptosis.

**PDIA6 facilitated OSCC cell migration and invasion**

In addition, we assessed PDIA6 role in cell migration and invasion in OSCC. Compared with the OE-NC group, cell migration (Figure 3A) and invasion (Figure 3B) were all apparently enhanced following PDIA6 overexpression in SCC9 and Cal27 cells, while knockdown of PDIA6 caused opposite results (Figure 3A-3B). These results indicated that PDIA6 served as an inducer in cell migration and invasion in OSCC.

**PDIA6 promoted aerobic glycolysis in OSCC**

Moreover, we evaluated the effect of PDIA6 in the aerobic glycolysis in OSCC cells. Compared with the OE-NC group, the glucose consumption (Figure 4A), lactate production (Figure 4B) and ATP level (Figure 4C) all were significantly increased in OE-PDIA6 group, and were decreased in si-PDIA6 group. These findings suggested that PDIA6 promoted aerobic glycolysis in OSCC.

**PDIA6 promoted the tumorigenesis of OSCC cells**

Finally, we detected PDIA6 role in the in vivo tumor formation ability of SCC9 cells. The result showed that, in comparison with the OE-NC group, the tumor weight and volume were increased when PDIA6 was upregulated in SCC9 cells (Figure 5A-5B), suggesting that PDIA6 enhanced cell tumorigenesis in OSCC.

**Discussion**

In the present study, we revealed that for the first time that PDIA6 was overexpressed in OSCC tissues, and served as an oncogene to promote OSCC growth, migration, invasion and *in vivo* tumor formation, and inhibit cell apoptosis through enhancing aerobic glycolysis in OSCC. Focusing on aerobic glycolysis, this study provides a potential therapeutic target for OSCC treatment.

Recently, evidence has demonstrated that PDI family members are frequently overexpressed in some cancers with poor prognosis, high incidence of invasion and chemoresistance (18). For instance, Ramos
et al (19) suggested that the expression levels of PDIA3 and PDIA6 were increased in primary ductal breast cancer. Bai et al (15) found that PDIA6 expression was increased in non-small cell lung cancer (NSCLC) tissues, which correlated with poor prognosis; further experiments showed that silencing of PDIA6 inhibited cell growth and promoted cell apoptosis induced by cisplatin, while augment of PDIA6 caused the opposite results. In OSCC, Yuan et al (20) used bioinformatics method and immunohistochemical assays, and observed that PDIA3 level was increased in OSCC tissues, which was further verified by the. Herein, we evaluated the expression profile of PDIA6 in OSCC tissues using qPCR and western blotting assays, and found that PDIA6 expression level was apparently increased in OSCC tissues. PDIA6 expression pattern in OSCC was consistent with NSCLC (15), bladder cancer (16), ovarian cancer (21) and hepatocellular carcinoma (17). Further analysis showed that higher level of PDIA6 in OSCC patients was closely associated with lower overall survival, higher TNM stage ($p = 0.006$), poorer tissue differentiation ($p = 0.036$) and perineural invasion ($p = 0.034$). Similarly, the PDIA6 expression level was associated with the presence of lymph node metastasis and hormone receptors status in breast cancer (19).

Through the gain- and loss-of-function assays, we found that PDIA6 overexpression significantly promoted the proliferation, invasion, migration and tumorigenesis of OSCC cells, and resulted in a marked decrease in cell apoptosis rate, illustrating that PDIA6 exerted an oncogenic role in OSCC progression. Up to now, PDIA6 has been verified to serve as an oncogene in several kinds of cancers. Inactivation of PDIA6 directly promoted cisplatin-induced cell death in NSCLC (22). Overexpression of PDIA6 caused an enhancement in cell proliferation accompanied with accelerated cell cycle progression in HeLa cells via activating wnt/β-catenin signaling (23). Silence of PDIA6 significantly inhibited bladder cancer cell proliferation, invasion, and in vivo tumor formation and metastasis [16]. Silencing of PDIA6 significantly decreased the tumor volumes to 42.7% in giant cell tumor stromal cells (24). However, glioblastoma U87MG cell migration and invasion were enhanced significantly after inhibition of PDIA6 (25), suggesting that PDIA6 might play an inhibitory role in cell migration and invasion in glioblastoma. The different cell contents might cause this difference.

It has been recognized that cancer cells present with high glycolytic metabolism even in the presence of oxygen (26, 27). Glycolysis is beneficial to cancer cells to meet their requirements to maintain rapid growth and migration via providing ATP and metabolic intermediates (28). Similarly to other solid cancer cells, OSCC cells also have been identified to obtain the energy needed for cell growth via aerobic glycolysis, and to require more aggressive behaviors (29, 30). In addition, Wei et al (31) revealed that glucose metabolism was significantly increased in premalignant dysplastic oral tissues and persisted as disease progression when compared to the normal oral mucosa tissues. These results indicate that glycolysis is closely implicated in pathogenesis of oral carcinogenesis. In the present study, we explored whether PDIA6 was involved in aerobic glycolysis. The results showed that overexpression of PDIA6 increased glucose consumption, lactate production and ATP level in OSCC cells. These results suggested that PDIA6 contributed to aerobic glycolysis in OSCC, leading to OSCC progression.
Conclusion

In summary, the current findings reveal that PDIA6 expression is elevated in OSCC, and predicted poor outcome and advanced clinical process for OSCC patients. Additionally, PDIA6 functions as an oncogene to promote OSCC growth, migration, invasion and \textit{in vivo} tumor formation, and inhibit cell apoptosis through enhancing aerobic glycolysis.

Abbreviations

OSCC, oral squamous cell carcinoma; NSCLC, non-small cell lung cancer; PDIA6, Protein disulfide isomerase family 6; LDHA, lactate dehydrogenase A; siRNAs, small interfering RNAs; qPCR, Real-time quantitative polymerase chain reaction.

Declarations

\textbf{Ethics approval and consent to participate} The written informed consents were signed by every patient. The current study involving human samples and animal experiment has got the approval of the ethics committee of Guizhou Medical University (No. 2001221).

\textbf{Consent for publication} Not applicable.

\textbf{Availability of data and materials} All data generated or analysed during this study are included in this published article.

\textbf{Competing interests} There are no conflicts of interest among the authors.

\textbf{Funding} This study was supported by the Guiyang Science and Technology Project (No. ZuKeHeTong[2019]-9-14-5) and the Guiyang Baiyun District Science and Technology Project (No. [2019]38#).

\textbf{Authors' contributions} Ling Mao and Xiaoweng Wu carried out most of the experiments and drafted the manuscript. Zhengpeng Gong did parts of the experiments and performed the statistical analysis; Ming Yu and Zhi Huang conceived of the study, and revised the manuscript. All authors read and approved the final manuscript.

\textbf{Acknowledgements} Not applicable.

\textbf{References}

1. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral oncology. 2009;45(4-5):309-16. Epub 2008/09/23.

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a
1. Vigneswaran N, Williams MD. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral and maxillofacial surgery clinics of North America. 2014;26(2):123-41. Epub 2014/05/06.

2. Bello IO, Soini Y, Salo T. Prognostic evaluation of oral tongue cancer: means, markers and perspectives (II). Oral oncology. 2010;46(9):636-43. Epub 2010/07/20.

3. Jerjes W, Upile T, Petrie A, Riskalla A, Hamdoon Z, Vourvachis M, et al. Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients. Head & neck oncology. 2010;2:9. Epub 2010/04/22.

4. Chen G, Zhang Y, Liang J, Li W, Zhu Y, Zhang M, et al. Deregulation of Hexokinase II Is Associated with Glycolysis, Autophagy, and the Epithelial-Mesenchymal Transition in Tongue Squamous Cell Carcinoma under Hypoxia. BioMed research international. 2018;2018:8480762. Epub 2018/04/24.

5. Chen G, Liu H, Zhang Y, Liang J, Zhu Y, Zhang M, et al. Silencing PFKP inhibits starvation-induced autophagy, glycolysis, and epithelial mesenchymal transition in oral squamous cell carcinoma. Experimental cell research. 2018;370(1):46-57. Epub 2018/06/13.

6. Lee M, Yoon JH. Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication. World journal of biological chemistry. 2015;6(3):148-61. Epub 2015/09/01.

7. Pennington Z, Goodwin ML, Westbroek EM, Cottrill E, Ahmed AK, Sciubba DM. Lactate and cancer: spinal metastases and potential therapeutic targets (part 2). Annals of translational medicine. 2019;7(10):221. Epub 2019/07/13.

8. Cui J, Shi M, Xie D, Wei D, Jia Z, Zheng S, et al. FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014;20(10):2595-606. Epub 2014/03/19.

9. Cai H, Li J, Zhang Y, Liao Y, Zhu Y, Wang C, et al. LDHA Promotes Oral Squamous Cell Carcinoma Progression Through Facilitating Glycolysis and Epithelial-Mesenchymal Transition. Frontiers in oncology. 2019;9:1446. Epub 2020/01/11.

10. Xu XD, Shao SX, Jiang HP, Cao YW, Wang YH, Yang XC, et al. Warburg effect or reverse Warburg effect? A review of cancer metabolism. Oncology research and treatment. 2015;38(3):117-22. Epub 2015/03/21.

11. Kikuchi M, Doi E, Tsujimoto I, Horibe T, Tsujimoto Y. Functional analysis of human P5, a protein disulfide isomerase homologue. Journal of biochemistry. 2002;132(3):451-5. Epub 2002/09/03.

12. Wang L, Wang X, Wang CC. Protein disulfide-isomerase, a folding catalyst and a redox-regulated chaperone. Free radical biology & medicine. 2015;83:305-13. Epub 2015/02/24.

13. Bai Y, Liu X, Qi X, Peng F, Li H, Fu H, et al. PDIA6 modulates apoptosis and autophagy of non-small cell lung cancer cells via the MAP4K1/JNK signaling pathway. EBioMedicine. 2019;42:311-25. Epub 2019/03/30.

14. Cheng HP, Liu Q, Li Y, Li XD, Zhu CY. The Inhibitory Effect of PDIA6 Downregulation on Bladder Cancer Cell Proliferation and Invasion. Oncology research. 2017;25(4):587-93. Epub 2016/10/21.
17. Negroni L, Taouji S, Arma D, Pallares-Lupon N, Leong K, Beausang LA, et al. Integrative quantitative proteomics unveils proteostasis imbalance in human hepatocellular carcinoma developed on nonfibrotic livers. Molecular & cellular proteomics : MCP. 2014;13(12):3473-83. Epub 2014/09/17.

18. Xu S, Sankar S, Neamati N. Protein disulfide isomerase: a promising target for cancer therapy. Drug discovery today. 2014;19(3):222-40. Epub 2013/11/05.

19. Ramos FS, Serino LT, Carvalho CM, Lima RS, Urban CA, Cavalli IJ, et al. PDIA3 and PDIA6 gene expression as an aggressiveness marker in primary ductal breast cancer. Genetics and molecular research : GMR. 2015;14(2):6960-7. Epub 2015/07/01.

20. He Y, Shao F, Pi W, Shi C, Chen Y, Gong D, et al. Larg-scale Transcriptomics Analysis Suggests Over-Expression of BGH3, MMP9 and PDIA3 in Oral Squamous Cell Carcinoma. PloS one. 2016;11(1):e0146530. Epub 2016/01/09.

21. Samanta S, Tamura S, Dubeau L, Mhawech-Fauceglia P, Miyagi Y, Kato H, et al. Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer. Oncotarget. 2017;8(61):103543-56. Epub 2017/12/22.

22. Tufo G, Jones AW, Wang Z, Hamelin J, Tajeddine N, Esposti DD, et al. The protein disulfide isomerases PDIA4 and PDIA6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma. Cell death and differentiation. 2014;21(5):685-95. Epub 2014/01/28.

23. Gao H, Sun B, Fu H, Chi X, Wang F, Qi X, et al. PDIA6 promotes the proliferation of HeLa cells through activating the Wnt/beta-catenin signaling pathway. Oncotarget. 2016;7(33):53289-98. Epub 2016/07/28.

24. Herr I, Sahr H, Zhao Z, Yin L, Omlor G, Lehner B, et al. MiR-127 and miR-376a act as tumor suppressors by in vivo targeting of COA1 and PDIA6 in giant cell tumor of bone. Cancer letters. 2017;409:49-55. Epub 2017/09/04.

25. Kim TW, Ryu HH, Li SY, Li CH, Lim SH, Jang WY, et al. PDIA6 regulation of ADAM17 shedding activity and EGFR-mediated migration and invasion of glioblastoma cells. Journal of neurosurgery. 2017;126(6):1829-38. Epub 2016/08/20.

26. Warburg O. On respiratory impairment in cancer cells. Science. 1956;124(3215):269-70. Epub 1956/08/10.

27. Weinhouse S. On respiratory impairment in cancer cells. Science. 1956;124(3215):267-9. Epub 1956/08/10.

28. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annual review of cell and developmental biology. 2011;27:441-64. Epub 2011/10/12.

29. Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2012;53(5):709-15. Epub 2012/04/12.

30. Clatot F, Gouerant S, Mareschal S, Comic M, Berghian A, Choussy O, et al. The gene expression profile of inflammatory, hypoxic and metabolic genes predicts the metastatic spread of human head and
Table 1
Primer sequences

| Gene   | Sense (5'-3')           | Antisense (5'-3')          |
|--------|-------------------------|---------------------------|
| PDIA6  | CACTAGGCGCTCACTGTTC     | GAGGGATCTCGCTCTGGAA       |
| β-actin| TGCCTGACATTAAGGAGAAG    | GCTCGTAGCTTTCTCCA         |
Table 2
Association of PDIA6 expression with clinicopathological features of OSCC patients.

| Characteristics          | Total number (n = 58) | PDIA6 expression | P value |
|--------------------------|-----------------------|------------------|---------|
|                          |                       | Low (n = 23)     | High (n = 35) |
| Age (years)              |                       |                  |         |
| ≤ 60                     | 32                    | 16               | 16      |
| > 60                     | 26                    | 7                | 19      |
| Gender                   |                       |                  |         |
| Male                     | 28                    | 12               | 16      |
| Female                   | 30                    | 11               | 19      |
| Tumor size (cm)          |                       |                  |         |
| < 3                      | 27                    | 13               | 14      |
| ≥ 3                      | 31                    | 10               | 21      |
| TNM stage                |                       |                  |         |
| I-II                     | 25                    | 15               | 10      |
| III-IV                   | 33                    | 8                | 25      |
| Tumor differentiation    |                       |                  |         |
| Well                     | 28                    | 15               | 13      |
| Moderate-Poor            | 30                    | 8                | 22      |
| Perineural invasion      |                       |                  |         |
| No                       | 33                    | 17               | 16      |
| Yes                      | 25                    | 6                | 19      |